Germany Seeks Covid Vaccine Doses Beyond EU Deal Allocation
Germany is conducting direct negotiations with domestic Covid-19 vaccine developers to obtain more doses than would be allocated through the shared European Union plan, Health Minister Jens Spahn said on Wednesday.
The country is in talks withBioNTech SE, Pfizer Inc.’s partner on the first vaccine approved in a Western country against the virus, as well asCureVac NV andIDT Biologika GmbH, Spahn said. All three German companies received funding through a government program to support Covid vaccine development.
The 27-member EU has slipped behind the U.K. — and most likely the U.S. — on its timeline for vaccine approval. Britain’s regulator signed off Wednesday on the Pfizer-BioNTech vaccine, while the U.S. Food and Drug Administration advisers will consider emergency authorization for the inoculation Dec. 10. European authorities have given themselves until Dec. 29 to review the application.
“We can’t be prohibited forever from buying additional vaccine doses on our own,” Spahn said. Talks with BioNTech and CureVac started only after it was established that the companies would be able to meet the stated demand of all EU member countries, he said.
180,083 in U.S.Most new cases today
+8% Change in MSCI World Index of global stocks since Wuhan lockdown, Jan. 23
-0.813 Change in U.S. treasury bond yield since Wuhan lockdown, Jan. 23
4% Global GDP Tracker (annualized), Oct.